Option chain shows key data for RF Acquisition Corp. - Rights's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for RF Acquisition Corp. - Rights.

RF Acquisition Corp. - Rights (NASDAQ:RFACR) Stock, Option Chain

RF Acquisition Corp. - Rights

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

COCP

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $7 Price Target

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $120 to $125.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $125

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $142 to $152.

Citigroup Maintains Neutral on 3M, Raises Price Target to $152

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Biotech

General

Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements

Global

P&G CFO Says Organic Sales In China Declined 3% In Q2

WIIM

ROKU

Roku shares are trading higher after Netflix reported strong quarterly earnings.

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

ATRA

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

United Airlines shares are trading higher after the company reported better-than-expected Q4 financial results.

IBKR

Interactive Brokers shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $965 to $1150.

Comments

RF Acquisition Corp. - Rights

RF Acquisition Corp. - Rights (RFACR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga